Sanofi (SNY) Will Outline Long-Term Roadmap; Sees Sales CAGR at 3% - 4% from 2015 -20

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Sanofi (SNY) Will Outline Long-Term Roadmap; Sees Sales CAGR at 3% - 4% from 2015 -20

UBS Downgrades Sanofi (SNY) to Neutral

November 9, 2015 8:45 AM EST

UBS downgraded Sanofi (NYSE: SNY) from Buy to Neutral.

For an analyst ratings summary and ratings history on Sanofi click here. For more ratings news on Sanofi click here.

Shares of Sanofi closed at $46.60 yesterday.

... More

Sanofi (SNY), Lexicon Pharma (LXRX) Enter Sotagliflozin Commercialization, Development Agreement

November 6, 2015 6:26 AM EST

Sanofi (NYSE: SNY) and Lexicon Pharma (Nasdaq: LXRX) announced that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.

"This agreement with Lexicon reinforces our commitment to helping people living with diabetes," said Pascale Witz, Executive Vice President, Sanofi, who will lead the Global Diabetes and Cardiovascular Care Business Unit in the company's new organizational structure. "Adding... More

MannKind (MNKD) Drops to Session Lows on Sanofi-Related Chatter

November 5, 2015 11:53 AM EST

MannKind (NASDAQ: MNKD) dropped to session lows Thursday, falling 11%. Chatter suggests the fall is tied to a meeting at Sanofi (NYSE: SNY) tomorrow, and possible fallout for MannKind given sluggish Afrezza sales.

Senior management representatives at... More